Trial Profile
Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL).
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary) ; Fenofibrate
- Indications Hypercholesterolaemia; Hypertriglyceridaemia
- Focus Pharmacodynamics
- Acronyms RAFAEL
- 25 Feb 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 07 Jul 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 07 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.